25 results for “nmosd”. Showing 25 of 39,449.
Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
NMOSD, N-Momentum or Inebilizumab in the study of NMOSD
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.
NMOSD differentiated NMOSD from MS and MOGAD (AUC = 0.897 and 0.843, respectively
Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.
NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), and multiple
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.
NMOSD eyes already had considerable neuroaxonal loss compared with HCs. In DN-NMOSD
NMOSD and MOGAD: an evolving disease spectrum.
NMOSD, MOGAD and double-seronegative NMOSD. MOGAD shares features with
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.
NMOSD cohorts note that some of the seronegative NMOSD cases
Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.
NMOSD) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple
ACSL4-mediated astrocyte ferroptosis augments neuroinflammation and exacerbates NMOSD pathology.
NMOSD) is recognized as a form of astrocytopathy; however, the mechanisms
Relapse-Independent disease activity in neuromyelitis optica spectrum disorder: A systematic review.
NMOSD. Our systematic review provides valuable insights into RIDA in NMOSD
APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model.
NMOSD. The protective effect of APOE in NMOSD pathogenesis was further
Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
NMOSD risk. CSF sTREM2 was elevated in patients with NMOSD
Double-negative neuromyelitis optica spectrum disorder.
NMOSD and may constitute a diagnostic and therapeutic challenge. DN NMOSD
Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta
Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.
NMOSD trial evaluated the safety and efficacy of ravulizumab in patients
MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease.
NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is crucial
Novel B-Cell targeting therapy with subcutaneous of atumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.
NMOSD) represent a distinct and rare subtype of Neuromyelitis Optica
Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders.
NMOSD) and myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are antibody
The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
NMOSD) patients (29 samples) and 13 healthy controls (HCs) (14 samples
Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
NMOSD) in patients who are aquaporin-4 immunoglobulin G (AQP4
Therapeutic updates in NMOSD and MOGAD: From present practice to future promise.
NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
NMOSD) has recently been defined and stratified based on AQP4
NMOSD and MOGAD.
NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The main
Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.
NMOSD) is a CNS autoimmune inflammatory disease mediated by T helper
Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering.
NMOSD = 36, double-seronegative NMOSD = 21, MOGAD = 15, AIDD = 80) followed
Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neuritis Associated With NMOSD, MOGAD, and MS.
NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Compared